Get the Stockscreener App
29.48
1.39%
0.405
Pre-market:
29.57
0.095
+0.32%
Centessa Pharmaceuticals Plc Adr stock is traded at $29.48, with a volume of 494.55K.
It is up +1.39% in the last 24 hours and up +24.16% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$29.07
Open:
$29
24h Volume:
494.55K
Relative Volume:
0.31
Market Cap:
$4.36B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-18.89
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
+1.71%
1M Performance:
+24.16%
6M Performance:
+135.24%
1Y Performance:
+71.77%
1-Day Range:
$28.52
$29.74
1-Week Range:
$28.19
$29.77
52-Week Range:
$9.60
$29.99
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
29.48 | 4.30B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Aug-29-25 | Resumed | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
B. Riley Research Analysts Raise Earnings Estimates for CNTA - MarketBeat
OMERS ADMINISTRATION Corp Buys New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
American Century Companies Inc. Raises Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
B. Riley Analysts Boost Earnings Estimates for CNTA - Defense World
Centessa Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:CNTA) - MarketBeat
Healthy Upside Potential: Centessa Pharmaceuticals plc ADR (CNTA) - Setenews
Milestone Pharmaceuticals Inc (MIST) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Grupo Supervielle S.A. ADR (SUPV) looking to reclaim success with recent performance - Setenews
The growth track for Tron Inc (TRON) has changed recently - Setenews
Taking the lead: Argo Blockchain Plc ADR (ARBK) - Setenews
Check out these key findings about Polestar Automotive Holding UK PLC ADR (PSNY) - Setenews
There is no way Rezolve AI PLC (RZLV) can keep these numbers up - Setenews
Check out these key findings about Nova Minerals Limited ADR (NVA) - Setenews
Check Out INVO Fertility Inc (IVF)’s Trade Data Rather Than the Analysts’ Views - Setenews
An analyst sees good growth prospects for Can-Fite Biopharma Ltd ADR (CANF) - Setenews
Stocks of Klarna Group plc (KLAR) are poised to climb above their peers - Setenews
Its Stock Has Paid Off Big Time For Aptera Motors Corp - Setenews
It makes sense and dollars to buy ATA Creativity Global ADR (AACG) stock - Setenews
Check out these key findings about Hub Cyber Security Ltd (HUBC) - Setenews
A better buy-in window may exist right now for Centessa Pharmaceuticals plc ADR (CNTA) - Setenews
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Views of Wall Street’s Leading Experts on Liminatus Pharma Inc - Setenews
Investors in cash trouble should check out Bonk Inc (BNKK) - Setenews
Brokers Set Expectations for CNTA FY2025 Earnings - Defense World
Centessa Pharmaceuticals stock hits all-time high at 29.31 USD By Investing.com - Investing.com Nigeria
Centessa Pharmaceuticals stock hits all-time high at 29.31 USD - Investing.com
CNTA: Phase 2 data show best-in-class efficacy and safety for orexin agonists in sleep disorders - TradingView
The time has not yet come to remove your chips from the table: Centessa Pharmaceuticals plc ADR (CNTA) - Setenews
Campbell & CO Investment Adviser LLC Acquires New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying - The Motley Fool
Centessa Pharma chief technology officer sells $1.04 million in shares By Investing.com - Investing.com India
Centessa Pharma chief technology officer sells $1.04 million in shares - Investing.com
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program - Finviz
Top investors say Vistra Corp (VST) ticks everything they need - setenews.com
[8-K] Centessa Pharmaceuticals plc Reports Material Event | CNTA SEC FilingForm 8-K - Stock Titan
[424B5] Centessa Pharmaceuticals plc Prospectus Supplement (Debt Securities) - Stock Titan
How does Xunlei Ltd ADR (XNET) change from a tortoise to a hare? - Setenews
AMD, Palantir among market cap stock movers on Wednesday By Investing.com - Investing.com UK
Centessa Pharmaceuticals stock hits 52-week high at $25.44 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals stock hits 52-week high at $25.44 - Investing.com
Centessa prices public offering of 11.6 million ADSs at $21.50 each By Investing.com - Investing.com South Africa
Centessa prices public offering of 11.6 million ADSs at $21.50 each - Investing.com India
Centessa Pharmaceuticals stock falls after announcing public offering - Investing.com
Centessa Pharmaceuticals stock falls after announcing public offering By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals launches public offering of ADSs By Investing.com - Investing.com India
Centessa Pharmaceuticals launches public offering of ADSs - Investing.com
Endava PLC Sponsored ADR (DAVA) Lags Q1 Earnings and Revenue Estimates - Yahoo Finance
What is Leerink Partnrs’ Estimate for CNTA FY2025 Earnings? - Defense World
Centessa Pharmaceuticals plc ADR (CNTA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
A Look at SRX Health Solutions Inc (SRXH) Shares in the Recent Past Indicates Growth - Setenews
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down Following Weak Earnings - Defense World
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):